Table 3. Effects of policosanol (Reduchole22^®) and orlistat treatment on related cholesterol parameters in HFD-induced mice model

Parameters	HFD-induced mice model
	Control (G1)1)	HFD (G2)	Orlistat (10 mg/kg, G3)	Policosanol (5 mg/kg, G4)	Policosanol (10 mg/kg, G5)	Policosanol (20 mg/kg, G6)
Initial body weight (g)	23.80±0.493)***	27.90±0.84	27.90±0.58	27.90±0.48	27.90±0.48	27.90±0.49
Final body weight (g)	33.40±1.15***	41.30±1.08	27.40±1.15***	36.80±0.83***	35.50±0.73***	31.90±0.43***
Total cholesterol (ng/mL)2)	117.75±6.14***	156.25±11.27	124.75±10.87***	128.50±10.94***	125.25±5.23***	121.75±6.86***
HDL-Cholesterol (ng/mL)	48.50±5.29***	29.25±5.01	48.75±6.14***	40.63±6.07***	46.50±4.00***	45.75±5.06***
LDL-Cholesterol (ng/mL)	84.75±2.92***	147.00±6.59	102.88±13.56***	110.63±5.73***	106.38±10.60***	101.50±4.57***
Atherogenic index	0.13±0.02***	0.25±0.003	0.15±0.03***	0.15±0.03***	0.14±0.02***	0.14±0.05***
HMG-CoA reductase in liver (HMGCR, ng/mL)	11.62±1.01***	17.04±1.05	10.89±2.75***	14.10±2.04*	13.60±2.51**	10.48±0.95***
Liver (g)	1.52±0.12***	1.89±0.27	1.59±0.11***	1.65±0.06**	1.67±0.03**	1.64±0.02**
Kidney (g)	0.29±0.06***	0.40±0.05	0.33±0.06*	0.36±0.03	0.39±0.04	0.37±0.02

Group 1 (G1), normal control group; Group 2 (G2), HFD-induced group; Group 3 (G3), treated orlistat drug (10 mg/kg) in HFD-induced group; Group 4 (G4), treated policosanol (5 mg/kg) in HFD-induced group; Group 5 (G5), treated policosanol (10 mg/kg) in HFD-induced group; Group 6 (G6), treated policosanol (20 mg/kg) in HFD-induced group.
The cholesterol parameters were measured by using liver and artery in mice.
All values are mean±SD (n=8).
p<0.05,
p<0.01, and
p<0.001 vs. Pathological control (HFD, G2).